Ex-Pfiz­er staffer found guilty of in­sid­er trad­ing af­ter buy­ing stock op­tions a day be­fore Paxlovid da­ta re­veal

A for­mer Pfiz­er em­ploy­ee was found guilty of buy­ing stock op­tions a day be­fore the com­pa­ny un­veiled pos­i­tive Covid-19 drug da­ta.

Amit Da­gar was a se­nior sta­tis­ti­cal pro­gram lead for the clin­i­cal tri­al of Paxlovid, Pfiz­er’s Covid an­tivi­ral, per an SEC doc­u­ment.

On Nov. 4, 2021, up­on learn­ing that the Paxlovid study yield­ed pos­i­tive re­sults, Da­gar bought Pfiz­er call op­tions, ac­cord­ing to fed­er­al pros­e­cu­tors. He then in­formed a friend, who al­so bought com­pa­ny call op­tions, be­fore the re­sults were to be made pub­lic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER